Zanubrutinib

Zanubrutinib
Clinical data
Trade names	Brukinsa
Other names	BGB-3111
AHFS/Drugs.com	Monograph
MedlinePlus	a620009
License data	US DailyMed: Zanubrutinib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
Drug class	Bruton's tyrosine kinase (BTK) inhibitor
ATC code	L01EL03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only; Rx-only;
Identifiers
CAS Number	1691249-45-2;
PubChem CID	135565884;
DrugBank	DB15035;
ChemSpider	64835237;
UNII	AG9MHG098Z;
KEGG	D11422;
ChEMBL	ChEMBL3936761;
PDB ligand	BA0 (PDBe, RCSB PDB);
Chemical and physical data
Formula	C27H29N5O3
Molar mass	471.561 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1;
	InChI InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1; ; Key:RNOAOAWBMHREKO-QFIPXVFZSA-N;

Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth.

It was approved for medical use in the United States in November 2019.